Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281781 · ClinicalTrials.gov registry record · Phase 1
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
A Phase 1 study of Myelofibrosis and Myelofibrosis; Anemia, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07281781: Recruiting Phase 1 study of Myelofibrosis and Myelofibrosis; Anemia, sponsored by University of California, Irvine.
NCT07281781 is a Phase 1 study of Myelofibrosis and Myelofibrosis; Anemia that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 10 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07281781, a Phase 1 study of Myelofibrosis and Myelofibrosis; Anemia, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
Primary Outcome
Comparison of Hepcidin Levels prior to and after Nelfinavir treatment
Conditions Studied
Interventions
- DRUG Nelfinavir
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT07281781 shows while recruiting
NCT07281781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Nelfinavir is the first listed.
NCT07281781 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07281781 about?
NCT07281781 is a clinical study titled "Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow". This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
What is the current status of trial NCT07281781?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-09-16. Estimated completion is 2027-06.
What conditions does trial NCT07281781 study?
This clinical trial studies the following conditions: Myelofibrosis, Myelofibrosis; Anemia.
What interventions are being tested in trial NCT07281781?
The interventions under investigation include: Nelfinavir (DRUG).
Who is sponsoring clinical trial NCT07281781?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07281781's enrollment target sits among peer trials
10 60th of 61 higher than 1 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI